{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T03:58:44Z","timestamp":1787630324838,"version":"build-2736575974"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T00:00:00Z","timestamp":1711670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Janssen Pharmaceutical Companies of Johnson & Johnson and Ferrer"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>We hypothesized that glucocorticoids would induce remission in very early systemic sclerosis (SSc) patients by inhibition of inflammation driving the disease. We examined the efficacy and safety of methylprednisolone in very early SSc.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this trial adults with puffy fingers for less than 3\u2009years, specific auto-antibodies and meeting the Very Early Diagnosis of Systemic Sclerosis criteria were randomly assigned (2:1) to methylprednisolone 1000\u2009mg i.v. or placebo for three consecutive days three times with monthly intervals. The primary end point was nailfold capillary density at week 12. Capillary density at 52\u2009weeks, number of megacapillaries and patient-reported outcomes were secondary outcomes. In addition, we assessed disease progression and lung function decline over 52\u2009weeks. We used linear regression analyses adjusted for baseline values and stratification variables to estimate differences between groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Between February 2017 and February 2021, 87 patients were screened, of whom 30 (70% female, median [interquartile range, IQR] age 52.9 [40.8\u201360.8] years, median [IQR] disease duration 11.4 [4.6\u201318.6] months) were randomly assigned to methylprednisolone (n\u2009=\u200921) or placebo (n\u2009=\u20099). We found no difference in nailfold capillary density at 12\u2009weeks (\u22120.5 [95% CI: \u22121.1, 0.2]) nor in any of the secondary outcomes. Eleven (37%) patients showed disease progression during 1\u2009year follow-up, and seven (23%) patients had a relevant pulmonary function decline. No serious adverse events were reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>No clinically relevant effect of short-term methylprednisolone in patients with very early SSc was observed. A substantial proportion of patients showed disease progression.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration<\/jats:title>\n                  <jats:p>clinicaltrials.gov, NCT03059979.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae156","type":"journal-article","created":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T22:56:23Z","timestamp":1711752983000},"page":"1261-1269","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy of methylprednisolone in very early systemic sclerosis: results of the \u2018Hit Hard and Early\u2019 randomized controlled trial"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0074-5286","authenticated-orcid":false,"given":"Brigit E","family":"Kersten","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Radboud University Medical Center , Nijmegen,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1183-5049","authenticated-orcid":false,"given":"Jacqueline M J","family":"Lemmers","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Radboud University Medical Center , Nijmegen,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1989-7060","authenticated-orcid":false,"given":"Amber","family":"Vanhaecke","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital Gent , Gent,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0700-7573","authenticated-orcid":false,"given":"Arthiha","family":"Velauthapillai","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Radboud University Medical Center , Nijmegen,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7706-7348","authenticated-orcid":false,"given":"Wieneke M T","family":"van den Hombergh","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Radboud University Medical Center , Nijmegen,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank H J","family":"van den Hoogen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Radboud University Medical Center , Nijmegen,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia H M","family":"van den Ende","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Radboud University Medical Center , Nijmegen,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6271-7945","authenticated-orcid":false,"given":"Vanessa","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital Gent , Gent,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madelon C","family":"Vonk","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Radboud University Medical Center , Nijmegen,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,29]]},"reference":[{"key":"2025030500184370200_keae156-B1","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2025030500184370200_keae156-B2","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/1744666X.2019.1614915","article-title":"Pathophysiology of systemic sclerosis: current understanding and new insights","volume":"15","author":"Cutolo","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"2025030500184370200_keae156-B3","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11926-012-0297-8","article-title":"The immune pathogenesis of scleroderma: context is everything","volume":"15","author":"Greenblatt","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"2025030500184370200_keae156-B4","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/ng.565","article-title":"Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus","volume":"42","author":"Radstake","year":"2010","journal-title":"Nat Genet"},{"key":"2025030500184370200_keae156-B5","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJMoa1114576","article-title":"Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis","volume":"370","author":"van Bon","year":"2014","journal-title":"N Engl J Med"},{"key":"2025030500184370200_keae156-B6","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"key":"2025030500184370200_keae156-B7","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2025030500184370200_keae156-B8","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1093\/rheumatology\/kez487","article-title":"Treatment with cyclophosphamide i.v. pulse therapy is an option for effective treatment of skin fibrosis in patients with early systemic sclerosis","volume":"59","author":"Kersten","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2025030500184370200_keae156-B9","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/rheumatology\/35.4.364","article-title":"Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial","volume":"35","author":"van den Hoogen","year":"1996","journal-title":"Br J Rheumatol"},{"key":"2025030500184370200_keae156-B10","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMra050541","article-title":"Antiinflammatory action of glucocorticoids\u2014new mechanisms for old drugs","volume":"353","author":"Rhen","year":"2005","journal-title":"N Engl J Med"},{"key":"2025030500184370200_keae156-B11","doi-asserted-by":"crossref","first-page":"R30","DOI":"10.1186\/ar2634","article-title":"High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy","volume":"11","author":"Hunzelmann","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"2025030500184370200_keae156-B12","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1177\/2397198320957552","article-title":"Clinical trial protocol: PRednisolone in early diffuse cutaneous Systemic Sclerosis (PRedSS)","volume":"6","author":"Herrick","year":"2021","journal-title":"J Scleroderma Relat Disord"},{"key":"2025030500184370200_keae156-B13","first-page":"1","article-title":"A Phase II randomized controlled trial of oral prednisolone in early diffuse cutaneous systemic sclerosis (PRedSS)","volume":"00","author":"Griffiths-Jones","year":"2023","journal-title":"Rheumatology"},{"key":"2025030500184370200_keae156-B14","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.3899\/jrheum.160791","article-title":"Evidence for a derangement of the microvascular system in patients with a very early diagnosis of systemic sclerosis","volume":"44","author":"Chora","year":"2017","journal-title":"J Rheumatol"},{"key":"2025030500184370200_keae156-B15","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s12016-009-8193-3","article-title":"The pathogenesis of systemic sclerosis revisited","volume":"40","author":"Geyer","year":"2011","journal-title":"Clin Rev Allergy Immunol"},{"key":"2025030500184370200_keae156-B16","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/ard.2010.136929","article-title":"Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group","volume":"70","author":"Avouac","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2025030500184370200_keae156-B17","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S2665-9913(21)00244-7","article-title":"Progression of patients with Raynaud\u2019s phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal Registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS)","volume":"3","author":"Bellando-Randone","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2025030500184370200_keae156-B18","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2174\/157339710904140417124819","article-title":"From Raynaud\u2019s phenomenon to very early diagnosis of systemic sclerosis- the VEDOSS approach","volume":"9","author":"Bellando-Randone","year":"2013","journal-title":"Curr Rheumatol Rev"},{"key":"2025030500184370200_keae156-B19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11926-017-0684-2","article-title":"Very early systemic sclerosis and pre-systemic sclerosis: definition, recognition, clinical relevance and future directions","volume":"19","author":"Bellando-Randone","year":"2017","journal-title":"Curr Rheumatol Rep"},{"key":"2025030500184370200_keae156-B20","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3899\/jrheum.190976","article-title":"The challenge of very early systemic sclerosis: a combination of mild and early disease?","volume":"48","author":"Blaja","year":"2021","journal-title":"J Rheumatol"},{"key":"2025030500184370200_keae156-B21","doi-asserted-by":"crossref","first-page":"e834","DOI":"10.1016\/S2665-9913(21)00244-7","article-title":"Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS)","volume":"3","author":"Bellando-Randone","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2025030500184370200_keae156-B22","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1136\/ard.2007.082495","article-title":"Autologous stem cell transplantation improves microcirculation in systemic sclerosis","volume":"68","author":"Miniati","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2025030500184370200_keae156-B23","first-page":"1993","article-title":"Improvement of microangiopathy after haematopoietic stem cell transplantation in systemic sclerosis","volume":"40","author":"Boonstra","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"2025030500184370200_keae156-B24","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1136\/ard.2009.115568","article-title":"Reliability of the qualitative and semiquantitative nailfold videocapillaroscopy assessment in a systemic sclerosis cohort: a two-centre study","volume":"69","author":"Smith","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2025030500184370200_keae156-B25","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/s13063-018-2798-x","article-title":"Hit hard and early: analysing the effects of high-dose methylprednisolone on nailfold capillary changes and biomarkers in very early systemic sclerosis: study protocol for a 12-week randomised controlled trial","volume":"19","author":"van den Hombergh","year":"2018","journal-title":"Trials"},{"key":"2025030500184370200_keae156-B26","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/ard.2008.096677","article-title":"EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)","volume":"68","author":"Kowal-Bielecka","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2025030500184370200_keae156-B27","doi-asserted-by":"crossref","first-page":"102458","DOI":"10.1016\/j.autrev.2020.102458","article-title":"Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis","volume":"19","author":"Smith","year":"2020","journal-title":"Autoimmun Rev"},{"key":"2025030500184370200_keae156-B28","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/annrheumdis-2020-217455","article-title":"Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database","volume":"80","author":"Hoffmann-Vold","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2025030500184370200_keae156-B29","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis: a simple staging system","volume":"177","author":"Goh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"2025030500184370200_keae156-B30","first-page":"1281","article-title":"Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis","volume":"22","author":"Clements","year":"1995","journal-title":"J Rheumatol"},{"key":"2025030500184370200_keae156-B31","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0248-8663(03)00268-6","article-title":"[Quality of life assessment with the MOS-SF36 in patients with systemic sclerosis]","volume":"25","author":"Georges","year":"2004","journal-title":"Rev Med Interne"},{"key":"2025030500184370200_keae156-B32","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/art.24730","article-title":"Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument","volume":"61","author":"Khanna","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2025030500184370200_keae156-B33","first-page":"832","article-title":"Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial","volume":"32","author":"Khanna","year":"2005","journal-title":"J Rheumatol"},{"key":"2025030500184370200_keae156-B34","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2025030500184370200_keae156-B35","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1093\/rheumatology\/keac079","article-title":"Nailfold capillaroscopy in SSc: innocent bystander or promising biomarker for novel severe organ involvement\/progression?","volume":"61","author":"Vanhaecke","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2025030500184370200_keae156-B36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1183\/13993003.02275-2016","article-title":"Screening for pulmonary arterial hypertension in an unselected prospective systemic sclerosis cohort","volume":"49","author":"Vandecasteele","year":"2017","journal-title":"Eur Respir J"},{"key":"2025030500184370200_keae156-B37","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.semarthrit.2021.07.018","article-title":"Incidence, prevalence and long-term progression of Goh algorithm rated interstitial lung disease in systemic sclerosis in two independent cohorts in flanders: a retrospective cohort study","volume":"51","author":"Vandecasteele","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2025030500184370200_keae156-B38","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1002\/art.24038","article-title":"Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis","volume":"58","author":"Koenig","year":"2008","journal-title":"Arthritis Rheum"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae156\/57312101\/keae156.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/3\/1261\/57312101\/keae156.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/3\/1261\/57312101\/keae156.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:21:57Z","timestamp":1741134117000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/3\/1261\/7637683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,29]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3,29]]},"published-print":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae156","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,3,29]]}}}